Henry Nisser’s practice is concentrated in national and international corporate law, with a particular focus on U.S. securities compliance, public as well as private M&A, equity and debt financings and corporate governance. He has drafted and negotiated agreements for reorganizations, share and asset purchases, indentures, public and private offerings, tender offers and going private transaction. Henry has also represented clients’ special committees established to evaluate M&A transactions and advised such committees’ members with respect to their fiduciary duties.
Henry is in frequent contact with representatives of the NASDAQ OMX Group, particularly in Stockholm, and has represented several Western European as well as Canadian entities in cross-border transactions. He recently represented Oasmia Pharmaceutical AB (NASDAQ: OASM) (NASDAQ Stockholm: OSAM.ST), a Swedish biopharmaceutical company focused on developing innovative treatments within human and animal oncology, in connection with Oasmia’s U.S. underwritten public offering of American Depository Shares. This marks the first Swedish uplisting to the U.S. NASDAQ capital markets.
Henry is fluent in French and Swedish and conversant in Italian.
Mr. Nisser received his B.A. from Connecticut College in 1992, where he majored in International Relations and Economics.
He received his LLB from the University of Buckingham School of Law in 1999.
Mr. Nisser is admitted to practice in the State of New York.
Mr. Nisser is fluent in French and Swedish, conversant in Italian.
Office: New York
Direct: (646) 810-0612